Mark M Smits

List of Publications by Citations

65 papers	2,309 citations	23 h-index	47 g-index
67 ext. papers	2,862 ext. citations	7.9 avg, IF	5.18 L-index

#	Paper	IF	Citations
65	Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1023-1039	12.7	303
64	Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 893-902	18.1	204
63	The clinical significance of pancreatic steatosis. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 8, 169-77	24.2	165
62	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. *Nature Reviews Nephrology*, **2017**, 13, 605-628	14.9	154
61	The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. *Nature Reviews Nephrology*, **2014**, 10, 88-103	14.9	127
60	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. *Kidney International*, **2020**, 97, 202-212	9.9	117
59	Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. *Pancreas*, **2010**, 39, 1185-90	2.6	111
58	Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. *Journal of Gastroenterology and Hepatology (Australia)*, **2013**, 28, 664-70	4	103
57	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. *Diabetologia*, **2016**, 59, 2588-2593	10.3	74
56	Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. *Diabetologia*, **2016**, 59, 1412-1421	10.3	74
55	Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. *Diabetes Care*, **2016**, 39, 2042-2050	14.6	66
54	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 367-81	18.1	63
53	Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. *Diabetes, Obesity and Metabolism*, **2016**, 18, 178-85	6.7	57
52	Understanding EMPA-REG OUTCOME. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 928-9	18.1	57
51	Smoking is related to pancreatic fibrosis in humans. *American Journal of Gastroenterology*, **2011**, 106, 1161-6; quiz 1167	0.7	50
50	Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. *British Journal of Clinical Pharmacology*, **2016**, 81, 613-20	3.8	44
49	Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. *Diabetes, Obesity and Metabolism*, **2016**, 18, 224-35	6.7	40

48	Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1669-1680	6.7	37
47	Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. *Cardiovascular Research*, **2020**, 116, 916-930	9.9	33
46	GLP-1 based therapies: clinical implications for gastroenterologists. *Gut*, **2016**, 65, 702-11	19.2	30
45	Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. *Diabetes, Obesity and Metabolism*, **2016**, 18, 1217-1225	6.7	30
44	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. *BMJ Open*, **2015**, 5, e009579	3	28
43	Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. *European Journal of Endocrinology*, **2017**, 176, 77-86	6.5	27
42	Exenatide improves □cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. *European Journal of Endocrinology*, **2016**, 175, 345-52	6.5	22
41	GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 2125-32	9.4	21
40	GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1538-43	9.4	20
39	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1235-1245	6.7	19
38	Herpes zoster after COVID vaccination. *International Journal of Infectious Diseases*, **2021**, 111, 169-171	10.5	16
37	Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. *Journal of Clinical Pharmacy and Therapeutics*, **2016**, 41, 116-8	2.2	15
36	Renal sinus fat and renal hemodynamics: a cross-sectional analysis. *Magnetic Resonance Materials in Physics, Biology, and Medicine*, **2020**, 33, 73-80	2.8	15
35	Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. *Annals of Epidemiology*, **2013**, 23, 415-21	6.4	14
34	Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. *American Journal of Physiology - Renal Physiology*, **2019**, 316, F231-F240	4.3	14
33	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. *Diabetes Research and Clinical Practice*, **2017**, 124, 1-10	7.4	13
32	Advances in pharmacologic therapies for type 2 diabetes. *Current Atherosclerosis Reports*, **2013**, 15, 302	6	13
31	Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. *Diabetes Care*, **2017**, 40, 301-308	14.6	11

30	Combining incretin-based drugs and RAAS inhibitors: more cons than pros?. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 684-5	18.1	11
29	Incretin-based drugs and renoprotection-is hyperfiltration key?. *Kidney International*, **2015**, 87, 660-1	9.9	9
28	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. *Diabetes Care*, **2016**, 39, e42-3	14.6	9
27	Renoprotection in LEADER and EMPA-REG OUTCOME. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 812-4	18.1	9
26	Arm length is associated with type 2 diabetes mellitus in Japanese-Americans. *Diabetologia*, **2012**, 55, 1679-84	10.3	8
25	Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. *Journal of Hypertension*, **2020**, 38, 1811-1819	1.9	7
24	Safety of Semaglutide. *Frontiers in Endocrinology*, **2021**, 12, 645563	5.7	7
23	Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients. *Hypertension*, **2018**, 72, 314-322	8.5	6
22	Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase. *Diabetes Research and Clinical Practice*, **2014**, 106, 617-26	7.4	6
21	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. *Diabetes Care*, **2020**, 43, 2889-2893	14.6	6
20	Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 881-885	2.4	5
19	Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial. *Diabetes, Obesity and Metabolism*, **2016**, 18, 281-8	6.7	5
18	Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance. *Microcirculation*, **2019**, 26, e12580	2.9	5
17	Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. *Diabetes and Metabolism*, **2021**, 47, 101223	5.4	5
16	Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1847-1856	6.7	4
15	Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands. *Journal of Diabetes and Metabolic Disorders*, **2021**, 1-6	2.5	4
14	Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes. *Diabetic Medicine*, **2017**, 34, 591-592	3.5	3
13	Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients. *Pancreas*, **2017**, 46, e75-e76	2.6	3

List of Publications

12	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. *Scientific Reports*, **2021**, 11, 10624	4.9	3
11	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.. *Cardiovascular Diabetology*, **2022**, 21, 63	8.7	2
10	Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098. *Diabetes Care*, **2015**, 38, e106-7	14.6	1
9	GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials. *Nutrition*, **2019**, 67-68, 110524	4.8	1
8	High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients. *Pancreas*, **2020**, 49, e5-e7	2.6	1
7	Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross-sectional study. *Microcirculation*, **2021**, 28, e12700	2.9	1
6	Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial. *Diabetes, Obesity and Metabolism*, **2022**, 24, 115-124	6.7	1
5	Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials.. *Journal of Diabetes and Its Complications*, **2022**, 36, 108127	3.2	0
4	Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function. *American Journal of Physiology - Renal Physiology*, **2021**, 320, F1152-F1158	4.3	0
3	PS9 - 1. Postprandial Haemodynamic Responses Are Altered in Uncomplicated Type 2 Diabetes. *Nederlands Tijdschrift Voor Diabetologie*, **2013**, 11, 157-157	0	
2	Plasma uric acid and renal haemodynamics in type 2 diabetes patients. *Nephrology*, **2020**, 25, 290-297	2.2	
1	Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity.. *Journal of Diabetes and Its Complications*, **2022**, 36, 108166	3.2	